Zura Bio Limited (ZURA)
(Delayed Data from NSDQ)
$3.77 USD
+0.07 (1.89%)
Updated Jul 25, 2024 04:00 PM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ZURA 3.77 +0.07(1.89%)
Will ZURA be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ZURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ZURA
Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know
How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84%
ZURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know
Other News for ZURA
3 Undervalued Biotech Stocks With Breakout Potential
Zura Bio Commences Warrant Exchange Offer and Consent Solicitation
Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024
Zura Bio Issues Informative Press Release, Excludes Legal Ties
Zura Bio presents data for tibulizumab program at EULAR 2024